Renal grafts from anti-hepatitis B core-positive donors: A quantitative review of the literature

Transplant Infectious Disease

Volumn 14, Issue 5, 2012, Pages 445-451

  Mahboobi, N ^a   Tabatabaei, S V ^b   Blum, H E ^c   Alavian, S M ^d  

^a Tehran Hepatitis Center   (Iran)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti HBc; HBV; Kidney transplantation

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

EMBASE; GRAFT RECIPIENT; HUMAN; INFECTION RISK; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEDLINE; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVIEW; SEROCONVERSION; VIRUS TRANSMISSION;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TISSUE DONORS;

EID: 84867628764     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00782.x     Document Type: Review

References (65)

1. Djamali A, Samaniego M, Muth B, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006; 1 (4): 623-640.
2. Chandraker A, Mannon RB. Care of the kidney transplant recipient. Clin J Am Soc Nephrol 2008; 3 (Suppl 2): S27-S28.
3. Rosenthal JT. Expanded criteria for cadaver organ donation in renal transplantation. Urol Clin North Am 1994; 21 (2): 283-292.
4. Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation. Nephron 2002; 90 (3): 241-251.
5. Wei HK, Loong CC, King KL, Wu CW, Lui WY. HBsAg(+) donor as a kidney transplantation deceased donor. Transplant Proc 2008; 40 (7): 2097-2099.
6. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91 (3): 412-413.
7. Turc Baron C, Pageaux GP, Mourad G. Outcome of HBs antigen positive kidneys after renal transplantation. Transplant Proc 1997; 29 (5): 2446.
8. Kairaitis LK, Gottlieb T, George CR. Fatal hepatitis B virus infection with fibrosing cholestatic hepatitis following renal transplantation. Nephrol Dial Transplant 1998; 13 (6): 1571-1573.
9. Hanson CA, Sutherland DE, Snover DC. Fulminant hepatic failure in an HBsAg carrier renal transplant patient following cessation of immunosuppressive therapy. Transplantation 1985; 39 (3): 311-312.
10. Verran D, Robertson A, Chapman J, Chadban S. The CARI guidelines. Decreased kidney donor suitability guidelines. Nephrology (Carlton) 2005; 10 (Suppl 4): S116-S132.
11. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992; 103 (2): 590-594.
12. Castells L, Vargas V, Rodriguez-Frias F, et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc 1999; 31 (6): 2464-2465.
13. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64 (11): 1582-1584.
14. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database. Gastroenterology 1997; 113 (5): 1668-1674.
15. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59 (2): 230-234.
16. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74 (4): 427-437.
17. Madayag RM, Johnson LB, Bartlett ST, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64 (12): 1781-1786.
18. Satterthwaite R, Ozgu I, Shidban H, et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64 (3): 432-435.
19. Fong TL, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002; 73 (1): 85-89.
20. Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol 2002; 15 (6): 605-613.
21. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult hepatitis B infection in chronic hemodialysis patients: current concepts and strategy. Hepat Mon 2010; 10 (3): 199-204.
22. Mahdavimazdeh M, Hosseini-Moghaddam SM, Alavian SM, Yahyazadeh H. Hepatitis B infection in hemodialysis patients in Tehran Province, Iran. Hepat Mon 2009; 9 (3): 206-210.
23. Agarwal SK. Hepatitis B infection during renal replacement therapy. Hepat Mon 2010; 10 (4): 255-257.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151 (4): W65-W94.
25. Cirocco R, Zucker K, Contreras N, et al. The presence of hepatitis B core antibody does not preclude kidney donation: lack of viral DNA in the serum and biopsies of core antibody-positive donors and clinical follow-up. Transplantation 1997; 63 (11): 1702-1703.
26. Krieger NR, Vial CM, Millan MT, Imperial J, Dafoe DC, Scandling JD. Revisiting the use of hepatitis B core antibody-positive donor kidneys. Transplant Proc 2001; 33 (1-2): 1535-1536.
27. Veroux M, Puliatti C, Gagliano M, et al. Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients. Transplant Proc 2005; 37 (6): 2574-2575.
28. Fytili P, Ciesek S, Manns MP, et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Transplantation 2006; 81 (5): 808-809.
29. De Feo TM, Grossi P, Poli F, et al. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006; 81 (1): 76-80.
30. Behzad-Behbahani A, Mojiri A, Tabei SZ, et al. Outcome of hepatitis B and C virus infection on graft function after renal transplantation. Transplant Proc 2005; 37 (7): 3045-3047.
31. De Feo TM, Poli F, Mozzi F, Moretti MP, Scalamogna M. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37 (2): 1238-1239.
32. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001; 165 (8): 1063-1064.
33. Burton JR Jr, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9 (8): 837-842.
34. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9 (10): 1053-1061.
35. Barcena R, Moraleda G, Moreno J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006; 12 (13): 2070-2074.
36. Fabrega E, Garcia-Suarez C, Guerra A, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003; 9 (9): 916-920.
37. Kwon CH, Suh KS, Cho JY, Yi NJ, Jang JJ, Lee KU. Change of hepatitis B virus DNA status in anti-HBc positive liver graft. Korean J Hepatol 2006; 12 (2): 191-200.
38. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52 (2): 272-279.
39. Hartwig MG, Patel V, Palmer SM, et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005; 80 (3): 320-325.
40. Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006; 81 (5): 1851-1852.
41. Dhillon GS, Levitt J, Mallidi H, et al. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for Organ Sharing database. Transplantation 2009; 88 (6): 842-846.
42. Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant 2005; 24 (1): 34-37.
43. Haji SA, Avery RK, Yamani MH, et al. Donor or recipient hepatitis B seropositivity is associated with allograft vasculopathy. J Heart Lung Transplant 2006; 25 (3): 294-297.
44. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005; 19 (3): 364-366.
45. Hoft RH, Pflugfelder SC, Forster RK, Ullman S, Polack FM, Schiff ER. Clinical evidence for hepatitis B transmission resulting from corneal transplantation. Cornea 1997; 16 (2): 132-137.
46. Mattern RM, Cavanagh HD. Should antibody to hepatitis B core antigen be tested in routine screening of donor corneas for transplant? Cornea 1997; 16 (2): 138-145.
47. Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 2006; 44 (6): 2250-2253.
48. Berger A, Preiser W, Kachel HG, Sturmer M, Doerr HW. HBV reactivation after kidney transplantation. J Clin Virol 2005; 32 (2): 162-165.
49. Miedouge M, Rostaing L, Mansuy JM, Sandres-Saune K, Boudet F, Izopet J. Screening for hepatitis B virus DNA in serum of organ donors and renal transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22 (4): 246-248.
50. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351 (8): 751-759.
51. Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010; 16 (11): 1314-1323.
52. Kuhns MC, Kleinman H, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004; 44 (9): 1332-1329.
53. Roque-Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50 (1): 95-99.
54. Lin CC, Chen CL, Concejero A, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007; 7 (1): 195-200.
55. Su WJ, Ho MC, Ni YH, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009; 48 (2): 203-208.
56. Casciato DA, McAdam LP, Kopple JD, et al. Immunologic abnormalities in hemodialysis patients: improvement after pyridoxine therapy. Nephron 1984; 38 (1): 9-16.
57. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer zum Buschenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986; 29 (6): 1209-1214.
58. Vanholder R, Van Loo A, Dhondt AM, De Smet R, Ringoir S. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 1996; 11 (4): 593-598.
59. Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 2009; 27 (41): 5654-5660.
60. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006; 24 (5): 789-796.
61. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32 (1): 1-10.
62. Veroux M, Corona D, Ekser B, et al. Kidney transplantation from hepatitis B virus core antibody-positive donors: prophylaxis with hepatitis B immunoglobulin. Transplant Proc 2011; 43 (4): 967-970.
63. Brock GN, Mostajabi F, Ferguson N, et al. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int 2011; 24 (6): 570-581.
64. Natov SN, Pereira BJG. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). Transpl Infect Dis 2002; 4 (3): 117-123.
65. Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis 2009; 1 (3): e2009025.